Efficacy of nab-paclitaxel in treating metastatic melanoma

References

• Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from the global burden of disease study 2015. Br J Dermatol. 2017 July;177(1):134–140.
   PubMed Web of Science ®Google Scholar
• Ultraviolet radiation (UV). World Health Organization. [cited 2018 Jul 20]. http://www.who.int/uv/faq/skincancer/en/index1.html
   Google Scholar
• Ward WH, Lambreton F, Goel N, et al. Clinical presentation and staging of melanoma. In: Ward WH1, Farma JM1, editors. Cutaneous melanoma: etiology and therapy [Internet]. Brisbane (AU): Codon Publications. 2017 Dec. Chapter 6.Clinical Presentation and Staging of Melanoma. 2017 December 21:79–89.
   Google Scholar
• Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015 April 1;33(10):1191–1196.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017 July 1;28(7):1631–1639.
   PubMed Web of Science ®Google Scholar
• Grossmann KF, Margolin K. Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol. 2015 May;7(3):181–191.
   PubMed Web of Science ®Google Scholar
• [cited 2018 Jul 20]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf
   Google Scholar
• Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008 October;19(9):899–909.
   PubMed Web of Science ®Google Scholar
• Chen N, Li Y, Ye Y, et al. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014 October;54(10):1097–1107.
   PubMed Web of Science ®Google Scholar
• Assessment Report for Abraxane. European Medicines Agency. [cited 2018 Jul 20]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000778/WC500020433.pdf
   Google Scholar
• Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008 July 1;14(13):4200–4205.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res. 2002 May;8(5):1038–1044.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 November 1;23(31):7794–7803.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996 June;14(6):1858–1867.
   PubMed Web of Science ®Google Scholar
• Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005 September 1;23(25):6019–6026.
   PubMed Web of Science ®Google Scholar
• Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005 November 1;23(31):7785–7793.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2008 February 1;26(4):639–643.
   PubMed Web of Science ®Google Scholar
• Hersh EM, Del VM, Brown MP, et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. Ann Oncol. 2015 November;26(11):2267–2274.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: a North Central cancer treatment group study, N0775. Cancer. 2013 February 1;119(3):586–592.
   PubMed Web of Science ®Google Scholar
• Kottschade LA, Suman VJ, Amatruda III T, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central cancer treatment group study, N057E(1). Cancer. 2011 April 15;117(8):1704–1710.
   PubMed Web of Science ®Google Scholar
• Em H, Sj O, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010 January 1;116(1):155–163.
   PubMed Web of Science ®Google Scholar
• LE S, Boasberg P, O’Day S, et al. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. Am J Clin Oncol. 2015 February;38(1):61–67.
   PubMed Web of Science ®Google Scholar
• Alrwas A, Papadopoulos NE, Cain S, et al. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma Res. 2014 August;24(4):342–348.
   PubMed Web of Science ®Google Scholar
• Ott PA, Chang J, Madden K, et al. Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. Cancer Chemother Pharmacol. 2013 January;71(1):183–191.
   PubMed Web of Science ®Google Scholar
• Vera-Aguilera J, Bedikian AY, Bassett RL, et al. Phase I/II study of hepatic arterial infusion of nab-paclitaxel in patients with Metastatic melanoma to the liver. Am J Clin Oncol. 2018 March 5. [Epub ahead of print]. doi: 10.1097/COC.0000000000000436.
   PubMed Web of Science ®Google Scholar
• ABRAXANETM for Injectable Suspension (paclitaxel protein-bound particlesfor injectable suspension) Info Sheet. [cited 2018 Jul 20]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021660lbl.pdf
   Google Scholar